Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

New JAMA issue focuses on infectious diseases and immunology

Several media outlets report on findings published in this week's issue of JAMA, which focuses on infectious diseases and immunology.

15 Apr 2011

Cancer screening updates

Everyone in England aged 55 to 59 will be invited for a new test which could dramatically cut their chances of developing bowel cancer. This new test could save an extra 3,000 lives every year after the UK National Screening Committee gave the nod for it to be added to the NHS programme. The test known as Flexible sigmoidoscopy (FS) differs to the current faecal occult blood (FOB) test, which relies on people sending off stool samples.

7 Apr 2011

People with lung cancer more likely to have high-risk forms of HPV antibodies

Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.

4 Apr 2011

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

International experts gather in Prague today for a three day meeting focused on the impact of vaccines on public health, at a time of increasing concern that public scepticism and complacency could undermine the positive impact of current and future vaccine campaigns.

31 Mar 2011

Scientists receive AACR Team Science Award for HPV research

The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus for more than 20 years.

28 Mar 2011

Graceway receives FDA approval for Zyclara Cream to treat genital warts

Graceway Pharmaceuticals announced today that the Food and Drug Administration has approved Zyclara Cream for the treatment of external genital and perianal warts in patients 12 years of age and older.

25 Mar 2011

Self-sample HPV test can help increase cervical screening uptake among women

Home tests for the human papillomavirus could help increase the take-up of cervical screening among women who do not respond to screening invitations, new research shows today.

16 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

Oral sex linked to cancer

Researchers from the United States have said that there is strong evidence linking oral sex to cancer. They have urged more study of how human papillomaviruses may be to blame for a rise in oral cancer among white men.

20 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Tulane surgeon performs new robotic-assisted surgery to treat head, neck cancers

Tulane University School of Medicine surgeon Dr. Paul Friedlander is performing a new, less-invasive form of robotic surgery to treat head and neck cancers.

9 Feb 2011

Anti-cancer shots for boys in the pipeline

The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.

8 Feb 2011

International research team receives AACR award for innovative, meritorious science

8 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus and rotavirus.

4 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011